Impact of the CLEAR Trial Data Updates in Clinical Practice
The panel discusses the potential impact of updated data from the CLEAR trial on the treatment of patients with advanced RCC in clinical practice.
CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings
Hans Hammers, MD, shares whether the updated CLEAR trial data would make him consider an IO-TKI regimen for patients with advanced RCC over an IO-IO regimen.
CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes
Brian Rini, MD, presents updated data from the CLEAR trial of lenvatinib plus pembrolizumab versus sunitinib in frontline advanced renal cell carcinoma.
Practice Pearls for Optimizing the Management of Advanced RCC
Experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, look toward the future treatment paradigm of both clear cell and non–clear cell renal cell carcinoma.
Role of Immunotherapy in Non–Clear Cell Renal Cell Carcinoma
Before closing out their discussion on renal cell carcinoma, key opinion leaders highlight efforts to optimize the management of non–clear cell disease with immunotherapy.
Advanced Renal Cell Carcinoma: What is the Role of Adjuvant Therapy?
Contextualizing discussion with clinical trial data and real-world experience, expert hematologist-oncologists consider the role of adjuvant therapy in managing advanced RCC.
Unmet Needs in the Management of Advanced Renal Cell Carcinoma
Shared insight from Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, on unmet needs in the setting of clear cell and non–clear cell renal cell carcinoma.
Novel Treatment Strategies in the Setting of Advanced Renal Cell Carcinoma
Key opinion leaders reflect on novel treatment modalities still under investigation for the management of advanced renal cell carcinoma.
Frontline Clinical Trial Data in Advanced Renal Cell Carcinoma
Expert hematologist-oncologists share comprehensive perspective on an array of first-line clinical trials in the setting of advanced renal cell carcinoma.
First-Line Therapy for Advanced RCC: Optimizing Adverse Event Management
A brief review of common adverse events inherent in the first-line management of advanced renal cell carcinoma and practical advice on how to mitigate treatment toxicity.
Overview of First-Line Treatment Options for Advanced RCC
Opening their discussion on the advanced renal cell carcinoma treatment landscape, experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, identify cornerstone first-line regimens.
Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.
The Exciting Future of Advanced Renal Cell Carcinoma Management
A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.
Unmet Needs in Advanced Renal Cell Carcinoma Management
Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.
Unmet Needs in the Front-Line Setting for Renal Cell Carcinoma
A look at the current unmet needs in front-line renal cell carcinoma treatment.
Patient Quality of Life on Lenvatinib plus Pembrolizumab Treatment for Renal Cell Carcinoma
Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.
Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma
Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
Dosing Lenvatinib for First-Line Renal Cell Carcinoma Treatment
An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.
Treating Favorable Risk Patients with Renal Cell Carcinoma with Lenvatinib
Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.
Risk Factors in the Management of Advanced Renal Cell Carcinoma
Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.
Choosing a Combination Treatment for Advanced Renal Cell Carcinoma
A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.
Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma
Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.
Impressions of Data and Results from the CLEAR Trial
Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.
Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”